Efficacy of Intravitreal Conbercept in Vitrectomy for Proliferative Diabetic Retinopathy: An Integrated Meta-Analysis and Bibliometric Study
Guangda Li, Mingxuan Zhang, Yifeng Ke, Chuanzhen Zheng, Liangzhang Tan, Yongtao Li, Emmanuel Eric Pazo, Chunli Chen, Xinjun Ren
Abstract
Purpose: To evaluate the effectiveness of intravitreal Conbercept administered before or during vitrectomy in patients with proliferative diabetic retinopathy (PDR), additionally, a bibliometric analysis was performed. Methods: The literature search was conducted using keywords and terms combined as follows: "conbercept", "vitrectomy", and "proliferative diabetic retinopathy", from January 2012 to August 2024. Additionally, we conducted three different comparisons. Data for the bibliometric analysis were obtained from the Web of Science database and analyzed using VOSviewer and Bibliometrix applications. Results: A total of 16 studies encompassing 1,215 cases were analyzed in this review. Patients in the Conbercept group demonstrated significantly greater improvements in best corrected visual acuity (BCVA) compared to the no injection group at six-month follow-ups (MD = -0.36, 95% CI -0.45 to -0.28, P < 0.01). Additionally, the Conbercept group experienced fewer intraoperative complications, including reduced incidences of intraoperative bleeding (OR = 0.12, 95% CI 0.07 to 0.21), use of endodiathermy (OR = 0.26, 95% CI 0.15 to 0.47), silicone oil tamponade (OR = 0.50, 95% CI 0.35 to 0.73), and iatrogenic breaks (OR = 0.25, 95% CI 0.13 to 0.48). Both early and late postoperative vitreous hemorrhages were less common in the Conbercept group. When administered during vitrectomy, Conbercept still showed superior BCVA improvement at six months (MD = -0.32, 95% CI -0.46 to -0.18, P < 0.01). No significant difference was found between Conbercept and Ranibizumab in BCVA or intraoperative outcomes. From 2015 to 2025, 5,065 publications on Conbercept emerged, with declining growth but strong global collaboration and relevance in anti-VEGF ocular therapy. Conclusion: This systematic review revealed that, similarly to other anti-VEGF injections, Conbercept injection improved BCVA and had lower rates of intraoperative and postoperative complications. Conbercept research shows strong global collaboration and evolving focus on clinical applications in retinal vascular disease management.
Keywords: conbercept; proliferative diabetic retinopathy; vitrectomy; intravitreal injection; anti-VEGF therapy; best-corrected visual acuity; intraoperative complications; vitreous hemorrhage
Access
How to cite
@article{li2025efficacy,
title = {{Efficacy of Intravitreal Conbercept in Vitrectomy for Proliferative Diabetic Retinopathy: An Integrated Meta-Analysis and Bibliometric Study}},
author = {Li, Guangda and Zhang, Mingxuan and Ke, Yifeng and Zheng, Chuanzhen and Tan, Liangzhang and Li, Yongtao and Pazo, Emmanuel Eric and Chen, Chunli and Ren, Xinjun},
journal = {Clinical ophthalmology},
year = {2025},
doi = {10.2147/opth.s516425},
url = {https://doi.org/10.2147/opth.s516425},
}
Related work
- Association between mean ocular perfusion pressure and proliferative diabetic retinopathy in a northern Chinese population (2026)
- Automated deep learning-based retinoschisis and detachment volume measurement in pathological myopia with posterior scleral contraction (2026)
- Development of a predictive model based on aqueous cytokines data for response to anti-VEGF therapy in diabetic macular edema (2026)
- Repeatability of cone photoreceptor metrics with a commercial adaptive optics scanning laser ophthalmoscopy (Mona II) in healthy adults (2026)
- Retinal and choroidal changes in diabetic patients before definitive diagnosis of diabetic retinopathy: a two-year prospective study (2026)